Cargando…
(1200) Evusheld Protects Against SARS-CoV-2 in Lung Transplant Recipients
PURPOSE: Evusheld (tixagevimab/cilgavimab), a combination of two monoclonal antibodies against SARS-CoV-2, was authorized in January 2022 as prophylaxis in immunocompromised patients. Data on Evusheld efficacy in lung transplant patients is lacking. This study aimed to determine if Evusheld reduces...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Published by Elsevier Inc.
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10068078/ http://dx.doi.org/10.1016/j.healun.2023.02.1410 |